Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 235 entries
View as:

Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09

Phase: N/A Priority: Normal
NCT ID: NCT02235493 Org: User:
Start: 08/31/14 End: 09/30/14 Due: 09/30/15

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT02301624 Org: User:
Start: 11/12/14 End: 01/15/19 Due: 01/15/20

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02193867 Org: User:
Start: 06/06/14 End: 10/30/18 Due: 10/30/19

Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05303324 Org: User:
Start: 07/04/19 End: 10/09/19 Due: 10/09/20

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05254613 Org: User:
Start: 11/12/19 End: 01/22/21 Due: 01/22/22

Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

Phase: N/A Priority: Normal
NCT ID: NCT00952484 Org: User:
Start: 09/30/09 End: 07/31/10 Due: 07/31/11

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Phase: N/A Priority: Normal
NCT ID: NCT06291376 Org: User:
Start: 03/29/24 End: 12/23/30 Due: 12/23/31

Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT01192425 Org: User:
Start: - End: - Due: -

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT06830798 Org: User:
Start: 05/19/25 End: 11/06/28 Due: 11/06/29

Early Access Program for ALXN1840 in Patients With Wilson Disease

Phase: N/A Priority: Normal
NCT ID: NCT05686564 Org: User:
Start: - End: - Due: -

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01883544 Org: User:
Start: 06/30/13 End: 01/31/14 Due: 01/31/15

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Phase: N/A Priority: Normal
NCT ID: NCT02949128 Org: User:
Start: 01/11/17 End: 01/24/23 Due: 01/24/24

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Phase: N/A Priority: Normal
NCT ID: NCT03748823 Org: User:
Start: 02/19/19 End: 08/31/23 Due: 08/31/24

The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

Phase: N/A Priority: Normal
NCT ID: NCT00438789 Org: User:
Start: - End: - Due: -

An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype

Phase: N/A Priority: Normal
NCT ID: NCT01528917 Org: User:
Start: 06/30/11 End: 05/31/13 Due: 05/31/14

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

Phase: N/A Priority: Normal
NCT ID: NCT04422431 Org: User:
Start: 12/02/20 End: 05/17/23 Due: 05/17/24

Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)

Phase: N/A Priority: Normal
NCT ID: NCT02797821 Org: User:
Start: 06/06/16 End: 06/21/17 Due: 06/21/18

A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06208488 Org: User:
Start: 11/22/23 End: 09/28/24 Due: 09/28/25

Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants

Phase: N/A Priority: Normal
NCT ID: NCT01700179 Org: User:
Start: 09/30/12 End: 09/30/13 Due: 09/30/14

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Phase: N/A Priority: Normal
NCT ID: NCT04469465 Org: User:
Start: 12/16/20 End: 01/16/24 Due: 01/16/25

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

Phase: N/A Priority: Normal
NCT ID: NCT04557735 Org: User:
Start: 12/07/20 End: 05/27/25 Due: 05/27/26

Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS

Phase: N/A Priority: Normal
NCT ID: NCT00844844 Org: User:
Start: 05/31/09 End: 07/31/13 Due: 07/31/14

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT00727194 Org: User:
Start: 10/31/08 End: 07/31/11 Due: 07/31/12

Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)

Phase: N/A Priority: Normal
NCT ID: NCT00894075 Org: User:
Start: 07/31/09 End: 12/31/14 Due: 12/31/15

A Study of a Single Dose of ALXN1210 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05288660 Org: User:
Start: 08/27/14 End: 03/13/15 Due: 03/13/16